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Although significant advances have been made in the
understanding of parasite and vector biology and the
treatment and prevention of malaria, Plasmodium falciparum
continues to inflict a considerable burden of disease,
particularly in sub-Saharan Africa, with infants and young
children bearing the greatest morbidity and mortality [1].
The introduction of ACT (artemisinin-based combination
therapy), especially Coartem® (artemether/lumefantrine;
AL), has had a significant impact on the treatment of
malaria. A large body of evidence supports consistently
high efficacy and safety, demonstrating crucial reliability
in vulnerable populations. The efficacy and safety of this
ACT have been clearly demonstrated in a clinical
development programme spanning 14 years and
enrolling approximately 5,000 patients. In trials
conducted in different malaria-endemic regions, AL has
consistently achieved 28-day PCR-corrected cure rates of
>95% in evaluable populations, and has shown a
favourable safety and tolerability profile [2–6]. The new
dispersible formulation of AL proved as safe and effective
as the regular tablets, achieving 28-day PCR-corrected cure
rates of >97% [5]. Furthermore, the gametocidal properties
of this ACT have been clearly demonstrated, suggesting a
favourable impact on malaria transmission [7].
Studies in Zambia and KwaZulu-Natal have demonstrated
the impressive impact that AL can have on malaria
morbidity and mortality and transmission, at the same
time providing cost savings, as presented in this
supplement, when used in combination with other
malaria control strategies [8–11].
With the increasing availability of generic forms of ACT,
it is important to be aware of quality assurance
considerations to be sure that the efficacy and safety of
these critical anti-malarials is not compromised.
Substandard products may contain lower-than-stated
doses, or packaging may not be supportive enough to
further understanding and adherence to treatment,
which could increase the burden of malaria and
promote resistance.
Ensuring prompt access to an effective anti-malarial,
particularly to remote rural communities in resource-
poor countries, is an ongoing challenge. Prescribing
health workers and their patients, particularly those who
rely on government supplies, continually battle a ‘drug is
out of stock’ syndrome. Rational and implementable
anti-malarial drug policies, which are essential decision-
support tools in the fight against resistance, are
impossible to develop or to implement without an
ensured supply of effective, quality assured drugs.
Increasingly, community deployment programmes are
proving successful in diagnosing and treating malaria
patients close to home. The Tigray project, conducted in
a remote, rural region of Ethiopia (presented in this
supplement [11]) demonstrates how the use of
community health workers to deliver prompt, effective
treatment can have a significant impact on malaria
morbidity and mortality, as well as easing the malaria
case load for health facilities [12]. However, this
intervention strategy will rely on the individual countries
being willing to deregulate ACT to over-the-counter
(OTC) drug status.
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Open AccessDiagnostic development represents a potentially powerful
strategy to simultaneously improve healthcare delivery
and delay emergence of resistance. In the current situation
of rapidly evolving malaria epidemiology, accurate
diagnosis and appropriate treatment of patients, with
both positive and negative results for malaria will be
crucial. Informing communities and health care providers
that not every fever is malarial in origin and urging them
to seek a test before administration of an anti-malarial
treatment remains a challenge due to entrenched beliefs
and prescribing habits.
Novartis has delivered more than 250 million treatments
of AL to malaria-endemic countries on a non-profit basis
since 2001, saving an estimated 630,000 lives, and has an
on-going commitment to serving vulnerable populations.
The recent innovation of a dispersible formulation of AL
for infants and young children demonstrates a patient-
centric approach – the recognition of an unmet medical
need followed by a considered response supported by a
rigorous clinical development programme. Infants and
young children are most vulnerable to malaria, and the
delivery of a formulation specifically designed to meet
their needs will hopefully represent a significant advance
in the successful treatment of this population.
Patient-centred care will be vital to encourage adherence
to new treatment algorithms developed in response to the
changing malaria environment in Africa. The proof of
efficacy alone is not sufficient – acceptability to both
prescribers and their patients is vital. The provision of
effective drugs such as AL and other forms of ACT, in
appropriate formulations, will encourage improved
adherence to drug regimens. Education and communi-
cation programmes to engage both healthcare providers
and the community will be essential in a new era of
malaria prevention and treatment. Ultimately, healthcare
delivery systems are crucial to ensure the effectiveness of
the medicine, and there needs to be a concerted effort to
improve the healthcare systems in Africa, both publicly
and privately.
The safety profile of AL in the clinical trials performed so
far has remained good. However, there is a need for
continued pharmacovigilance to seek any rare untoward
effect and the INDEPTH effectiveness and safety studies of
anti-malarial drugs in Africa (INESS) will provide the
much-needed pharmacovigilance data to supplement the
limited spontaneous reporting of adverse events from
Africa [13]. The INESS project will help to sensitize and
train patients and health care professionals in pharma-
covigilance reporting, which is so far limited in Africa
through the existing systems in place supported by
organizations such as WHO, local health authorities or
marketing authorization holders.
This supplement reviews the contribution made by AL as
an ACT to the tremendous progress made in the control
of malaria and establishes effective treatment as a
cornerstone in the foundation of effective, quality patient
care for infants, children and adults with malaria.
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